Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients

The world population is aging, and cardiovascular diseases are the leading cause of death in Western countries. 

It is increasingly common to find patients aged 70 or older with non-ST-segment elevation acute myocardial infarction (NSTEMI). However, this group has been excluded from most studies, and there is not enough information to determine whether a conservative approach or invasive studies should be the preferred option.

Researchers conducted a meta-analysis including 1479 patients, half of whom underwent invasive treatment (INV) while the other half received conservative treatment (CON).

The primary endpoint (PEP) was all-cause mortality or myocardial infarction at one year of follow-up.

There were no significant differences in the studied population: the mean age was 84 years and 52% of patients were men; 79% had hypertension, 29% had diabetes, 15% had suffered a stroke, 35% had a previous myocardial infarction, 20% had undergone percutaneous coronary intervention (PCI), 13% had undergone myocardial revasculatization surgery, and 15% had atrial fibrillation.

Read also: QFR Analysis of Coronary Lesions with TAVR.

There were also no differences in the Killip classification at admission; most subjects were in Killip class 1.

The PEP at one year was similar between groups: 24.5% in the INV group and 28.9% in the CON group (95% confidence interval [CI]: 0.63–1.22; P = 0.43). There were no differences in mortality, but patients who received conservative treatment had a higher rate of myocardial infarction (19.1% vs. 12.2%, 95% CI 0.47–0.79; P = 0.0002) and a greater need for urgent revascularization (random-effects model hazard ratio [HR]: 0.41; 95% CI, 0.18–0.95; P = 0.037).

Conclusion

There was no evidence that routine invasive treatment in elderly patients with NSTEMI reduces the risk of all-cause mortality or myocardial infarction within one year compared with conservative treatment. However, there is compelling evidence that invasive treatment reduces the risk of recurrent myocardial infarction or need for urgent revascularization. More research through large-scale studies is needed.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysis.

Reference: Christos P. Kotanidis, et al. European Heart Journal (2024) 45, 2052–2062 https://doi.org/10.1093/eurheartj/ehae151


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...